	US 12,435,309 B2
	Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
Ann Marie Leen, Houston, TX (US); Ulrike Gerdemann, Cambridge, MA (US); Cliona M. Rooney, Bellaire, TX (US); Juan F. Vera Valdes, Houston, TX (US); and John R. Wilson, New Brighton, MN (US)
Assigned to Baylor College of Medicine, Houston, TX (US); and Wilson Wolf Manufacturing, New Brighton, MN (US)
Filed by Baylor College of Medicine, Houston, TX (US); and Wilson Wolf Manufacturing, New Brighton, MN (US)
Filed on May 26, 2022, as Appl. No. 17/804,239.
Application 17/804,239 is a continuation of application No. 16/408,093, filed on May 9, 2019, abandoned.
Application 16/408,093 is a continuation of application No. 16/246,369, filed on Jan. 11, 2019, abandoned.
Application 16/246,369 is a continuation of application No. 15/246,241, filed on Aug. 24, 2016, granted, now 10,385,316, issued on Aug. 20, 2019.
Application 15/246,241 is a continuation of application No. 12/862,409, filed on Aug. 24, 2010, granted, now 9,963,677, issued on May 8, 2018.
Claims priority of provisional application 61/236,261, filed on Aug. 24, 2009.
Prior Publication US 2022/0282218 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 40/11 (2025.01); A61K 39/12 (2006.01); A61K 39/155 (2006.01); A61K 39/245 (2006.01); A61K 40/22 (2025.01); A61K 40/41 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); A61K 39/245 (2013.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/418 (2025.01); A61K 40/424 (2025.01); A61K 40/4266 (2025.01); A61K 40/4267 (2025.01); A61K 40/4268 (2025.01); A61K 40/4269 (2025.01); A61K 40/427 (2025.01); A61K 40/4273 (2025.01); A61K 40/46 (2025.01); C12N 5/0638 (2013.01); A61K 2039/54 (2013.01); A61K 2039/572 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2501/23 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/11 (2013.01)]

8 Claims

1. A method of producing a cultured polyclonal population of cytotoxic T-lymphocytes (CTLs) that recognize at least one epitope from each of at least two different tumor antigens, said population comprising CD4+ T-lymphocytes and CD8+ T-lymphocytes, comprising the steps of:

ia) stimulating DCs or PBMCs with at least two libraries of peptides that each represent at least one epitope from each of at least two different tumor antigens to generate antigen presenting cells (APCs) and stimulating T cells with the APCs to generate antigen-specific T lymphocytes; or

ib) stimulating PBMCs with at least two libraries of peptides that each represent at least one epitope from each of at least two different tumor antigens to generate antigen-specific T-lymphocytes; and

ii) culturing the antigen-specific T-lymphocytes in the presence of IL-7 and IL-15 to generate a population of CTLs.